摘要:目的:探討鼻咽癌放療后程同步輔以小劑量順鉑增敏的近期療效,并與常規治療和后程加速超分割放射治療進行比較。方法:選取98例Ⅱ～Ⅳ期鼻咽癌患者,隨機分為常規治療組(簡稱T1組,32例)、后程加速超分割治療組(簡稱T2組,32例)和順鉑加后程加速超分割治療組(簡稱T3組,34例),并對治療效果進行比較。 結果:1組鼻咽部腫瘤消除率為75.0%(24／32),頸部淋巴結消除率為87.5%(28/32);T2組鼻咽部腫瘤消除率為87.5%(28／32),頸部淋巴結消除率為84.4%(27/32);T3組鼻咽部腫瘤消除率為97.1%(33／34),頸部淋巴結消除率為91.2%(31/34)。進行兩兩比較,均為P＜0.05,有統計學意義,療效:T3 組＞T2 組＞T1組。治療副作用有增加(P＞0.05),但無統計學意義。 結論:小劑量順鉑加后程加速超分割治療鼻咽癌,可以達到較常規治療更好的近期治療效果。
Abstract: Objective: To study the later therapeutic efficacy of nasopharyngeal carcinoma in late course accelerated fractionation (LCAF) radiotherapy and low dose cisplatin, at same time compare with conventional fractionation and LCAF. Methods: Ninetyeight cases with stage ⅡⅣ of nasopharyngeal carcinoma were randomly assigned to three groups: conventional fractionation (T1), LCAF (T2), LCAF and low dose cisplatin (T3). At the end of treatment, therapeutic efficacy was compared with each other. Results: The survey periods was 3 months. Comlete response rate (CR) for groups T1, T2 and T3 was 75.0% (24／32), 87.5% (28／32) and 97.1% (33／34), respectively; the group treated with LCAF and cisplatin had highest effective later therapeutic efficacy than other groups. Lymph node of neck of group T3 got better control, although its side effects were more serious, but no significant difference was found among three group. Conclusion: Combined treatment of LCAF radiotherapy and low dose cisplatin has better later therapeutic efficacy on tumor control in patients with nasopharyngeal carcinoma

引用本文： 劉煥義,潘興國,駱建華. 鼻咽癌小劑量順鉑增敏輔助放療的臨床研究. 華西醫學, 2009, 24(11): 3018-3019. doi: 復制